Tauriga Sciences, Inc. (OTC PINK: TAUG), engaged in the building of life sciences businesses and technologies, today announced that it has secured $80,000 USD in financing from GS Capital Partners, LLC ("GS Capital"), a New York based small institutional investor. This financing is comprised of a 5% interest bearing Promissory Note with a fixed conversion price of $0.00125 per share and a term of twelve months. This conversion price will not drop below the price of $0.00125 unless the Company enters into an agreement which offers a more favorable conversion discount.

In addition, the Company will immediately issue to GS Capital 5,000,000 "restricted" shares of the Company's common stock and a 5-year warrant to purchase 16,000,000 shares of the Company's common stock at an exercise price of $0.0035 per share. The Company has agreed to reserve 67,200,000 shares of common stock with its transfer agent pursuant to this Promissory Note. This 67,200,000 is inclusive of the 5% interest as it would apply to the overall investment. The $80,000, on its own, would convert into 64,000,000 shares at the established fixed price of $0.00125 per share.

A Form 8-K will filed within the next four business days, fully disclosing the material terms and conditions of this financing.

Tauriga's Chief Executive Officer, Seth M. Shaw, commented, "The Company is pleased to have completed this financing at terms it considers to be both beneficial to its shareholders and mindful to dilution. The Company plans to continue its efforts to repay and retire its existing convertible debt that does not incorporate this type of fixed price conversion feature. The Company continues to realize important progress on multiple fronts and looks forward to building the type of foundation conducive to a successful future."

ABOUT TAURIGA SCIENCES, INC.

Tauriga Sciences, Inc. (OTC PINK: TAUG) is a life sciences company engaged in the development, marketing, distribution and potential licensing of a broad array of products and technologies that may help individuals who are affected by muscle tension. The Company has already identified potential products and technologies of interest and is actively working towards the goal of creating an innovative product line to launch the business activities of ColluMauxil Therapeutics LLC (The Company's previously announced new planned wholly owned subsidiary). The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments. The Company is also prosecuting (as Plaintiff) its ongoing malpractice lawsuit agai nst its predecessor audit firm, for which it's seeking monetary damages in excess of $4,500,000 USD.